Trial · NCT05459181
HeartCare Immuno-optimization in Cardiac Allografts (MOSAIC)
NCT05459181, Not applicable, Unknown, CareDx
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. HeartCare Immuno-optimization in Cardiac Allografts (MOSAIC). Trials, record NCT05459181. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05459181
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- HeartCare Immuno-optimization in Cardiac Allografts (MOSAIC)
- NCT number
- NCT05459181
- Status
- Unknown
- Phases
- Not applicable
- Enrollment
- 930 participants, estimated
- Lead sponsor
- CareDx
- Conditions
- Heart Transplant, Immunosuppression, Allograft
- Interventions
- HeartCare
- First posted
- 2022-07-14
- Last updated
- 2024-10-23
Source ClinicalTrials.gov
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of Allograft loss at 12-months post-transplant (safety) | 12 months | Demonstrate the safety and efficacy of HeartCare as a tool to successfully optimize immunosuppressant agents using regular surveillance for safe drug minimization. |
| Primary | Incidence of Allograft loss at 24-months post-transplant (safety) | 24 months | Demonstrate the safety and efficacy of HeartCare as a tool to successfully optimize immunosuppressant agents using regular surveillance for safe drug minimization. |
| Primary | Total number of acute rejection episodes (ACR >2R or AMR*) at 12-months post-transplant (safety) | 12 months | Demonstrate the safety and efficacy of HeartCare as a tool to successfully optimize immunosuppressant agents using regular surveillance for safe drug minimization. |
| Primary | Total number of acute rejection episodes (ACR >2R or AMR*) at 24-months post-transplant (safety) | 24 months | Demonstrate the safety and efficacy of HeartCare as a tool to successfully optimize immunosuppressant agents using regular surveillance for safe drug minimization. |
| Primary | EQ-5D survey performed at 12-months post-transplant to assess allograft function (safety) | 12 months | Demonstrate the safety and efficacy of HeartCare as a tool to successfully optimize immunosuppressant agents using regular surveillance for safe drug minimization. |
| Primary | TTE imaging performed at 12-months post-transplant to assess allograft function (safety) | 12 months | Demonstrate the safety and efficacy of HeartCare as a tool to successfully optimize immunosuppressant agents using regular surveillance for safe drug minimization. |
| Primary | EQ-5D survey performed at 24-months post-transplant to assess allograft function (safety) | 24 months | Demonstrate the safety and efficacy of HeartCare as a tool to successfully optimize immunosuppressant agents using regular surveillance for safe drug minimization. |
| Primary | TTE imaging performed at 24-months post-transplant to assess allograft function (safety) | 24 months | Demonstrate the safety and efficacy of HeartCare as a tool to successfully optimize immunosuppressant agents using regular surveillance for safe drug minimization. |
| Primary | Incidence of dnDSA formation at 12-months post-transplant (safety and efficacy) | 12 months | Demonstrate the safety and efficacy of HeartCare as a tool to successfully optimize immunosuppressant agents using regular surveillance for safe drug minimization. |
| Primary | Incidence of dnDSA formation at 24-months post-transplant (safety and efficacy) | 24 months | Demonstrate the safety and efficacy of HeartCare as a tool to successfully optimize immunosuppressant agents using regular surveillance for safe drug minimization. |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05459181
GET https://conductscience.org/api/trials/v1/NCT05459181/registered